Skip to main content
. 2000 Jul 3;192(1):41–52. doi: 10.1084/jem.192.1.41

Figure 1.

Figure 1

Intranasal administration of pCMV-TGF-β1 prevented TNBS-induced colitis in SJL/J mice. Weight changes (mean ± SD) of one experiment representative of three independent experiments is shown. Each group consists of 10 mice treated intranasally on day 0 with pCMV-TGF-β1 (100 μg/mouse). Alone, □; pCMV-TGF-β1 (100 μg intranasally) plus rectal instillation of TNBS (2.5 mg/mouse), ○; pCMV-TGF-β1 (100 μg intranasally) plus rectal instillation of TNBS (2.5 mg) and anti–IL-10 mAbs (SXC-1 and SXC-2 intraperitoneally 1 mg each/mouse), ▵; rectal instillation of TNBS alone (2.5 mg), •.